Combined treatment of inetetamab plus pyrotinib and vinorelbine in managing advanced HER2-positive breast cancer patients (ILLUMINE): a multicenter, retrospective, real-world study
{{output}}
Background: Breast cancer is the most common tumor among women worldwide, which human epidermal growth factor receptor 2 (HER2)-positive subtype accounts for approximately 15-20%. Although anti-HER2 agents have already diversifie... ...
